抗Fractalkine抗体(Anti-Fractalkine, Human, Goat-Poly antibody)

掲載日情報:2019/10/21 現在Webページ番号:26948

Fractalkineに対する抗体(Anti-Fractalkine, Human, Goat-Poly )です。
本製品は研究用です。研究用以外には使用できません。

価格

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
Anti-Fractalkine, Human, Goat-Poly
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 26
説明文
IHCにはABCキット(VEC社)の併用を推奨。
別名:ABCD-3
Genbank No: 6376
Protein Accession No: Q6I9S9
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 Human 免疫動物 Goat クラス IgG 標識 Unlabeled
交差性 Human 適用 Neutralising,Western Blot
クロナリティ Polyclonal フォーマット 性状 Antigen Affinity Purified 吸収処理
掲載カタログ

製品記事
関連記事
Anti-Human CX3CL1/Fractalkine Affinity Purified Polyclonal Ab
2~3週間 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 1
説明文
※受注発注品。形状:溶液または凍結乾燥
別名:ABCD-3
Genbank No: 6376
Protein Accession No: Q6I9S9
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 免疫動物 Goat クラス IgG 標識 Unlabeled
交差性 Human 適用 Neutralising,Western Blot
クロナリティ Polyclonal フォーマット 性状 Antigen Affinity Purified 吸収処理
掲載カタログ

製品記事 M1/M2 Macrophage Activation Marker
関連記事

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Anti-Fractalkine, Human, Goat-Poly

文献数: 26

説明文 IHCにはABCキット(VEC社)の併用を推奨。
別名:ABCD-3
Genbank No: 6376
Protein Accession No: Q6I9S9
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 Human 免疫動物 Goat
交差性 Human 適用 Neutralising,Western Blot
標識 Unlabeled 性状 Antigen Affinity Purified
吸収処理 クラス IgG
クロナリティ Polyclonal フォーマット
掲載カタログ

製品記事
関連記事

Anti-Human CX3CL1/Fractalkine Affinity Purified Polyclonal Ab

文献数: 1

説明文 ※受注発注品。形状:溶液または凍結乾燥
別名:ABCD-3
Genbank No: 6376
Protein Accession No: Q6I9S9
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 免疫動物 Goat
交差性 Human 適用 Neutralising,Western Blot
標識 Unlabeled 性状 Antigen Affinity Purified
吸収処理 クラス IgG
クロナリティ Polyclonal フォーマット
掲載カタログ

製品記事 M1/M2 Macrophage Activation Marker
関連記事



目次に戻る

Product Details

Species ReactivityHuman
LabelUnconjugated
ImmunogenE. coli-derived recombinant human CX3CL1/FractalkineGln25-Gly100Accession # Q6I9S9
SourcePolyclonal Goat IgG
PurificationAntigen Affinity-purified
SpecificityDetects human CX3CL1/Fractalkine in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant mouse CX3CL1 and recombinant rat CX3CL1 is observed and less than 10% cross-reactivity with recombinant human (rh) MCP‑2 and rhMCP-4 is observed.


目次に戻る

Applications and Data

 Recommended
Concentration
Sample
Western Blot0.1 µg/mLRecombinant Human CX3CL1/Fractalkine Chemokine Domain (Catalog # 362-CX)
Immunohistochemistry5-15 µg/mLSee below
NeutralizationMeasured by its ability to neutralize CX3CL1/Fractalkine-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with mouse CX3CR1. The Neutralization Dose (ND50) is typically 0.75-4.5 µg/mL in the presence of 100 ng/mL Recombinant Human CX3CL1/Fractalkine.


Neutralization
Chemotaxis Induced by CX3CL1/Fractalkine and Neutralization by Human CX3CL1/Fractalkine Antibody.
Recombinant Human CX3CL1/Fractalkine (Catalog # 365-FR) chemoattracts the BaF3 mouse pro‑B cell line transfected with mouse CX3CR1 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CX3CL1/Fractalkine (100 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CX3CL1/Fractalkine Chemokine Domain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF365). The ND50 is typically 0.75-4.5 µg/mL.
Immunohistochemistry
CX3CL1/Fractalkine in Human Breast Cancer Tissue.
CX3CL1/Fractalkine was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using 15 µg/mL Goat Anti-Human CX3CL1/Fractalkine Chemokine Domain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF365) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.


目次に戻る

Related Product & Information

Entrez Gene IDs6376 (Human); 20312 (Mouse); 89808 (Rat)
BackgroundCX3CL1/Fractalkine
background_contentBackground:
CX3CL1/Fractalkine
CX3CL1, also named neurotactin, is a novel chemokine identified through bioinformatics. CX3CL1 has a unique C-X3-C cysteine motif near the amino-terminus and is the first member of a fourth branch of the chemokine superfamily. Unlike other known chemokines, CX3CL1 is a type 1 membrane protein containing a chemokine domain tethered on a long mucin-like stalk. Human CX3CL1 cDNA encodes a 397 amino acid (aa) residue membrane protein with a 24 aa residue predicted signal peptide, a 76 aa residue chemokine domain, a 241 aa residue stalk region containing 17 degenerate mucin-like repeats, a 19 aa residue transmembrane segment and a 37 aa residue cytoplasmic domain. The extracellular domain of human CX3CL1 can be released, possibly by proteolysis at the dibasic cleavage site proximal to the membrane, to generate soluble CX3CL1. CX3CL1 mRNA has been detected in various tissues including the brain and heart. The expression of CX3CL1 was also reported to be up-regulated in endothelial cells and microglia by inflammatory signals. Membrane-bound CX3CL1 has been shown to promote adhesion of leukocytes. The soluble chemokine domain of human CX3CL1 was reported to be chemotactic for T cells and monocytes while the soluble chemokine domain of mouse CX3CL1 was reported to chemoattract neutrophils and T-lymphocytes but not monocytes. The gene for human CX3CL1 has been mapped to chromosome 16q.


目次に戻る

Citations

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
  1. The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination.
    Authors: Erreni M, Siddiqui I, Marelli G, Grizzi F, Bianchi P, Morone D, Marchesi F, Celesti G, Pesce S, Doni A, Rumio C, Roncalli M, Laghi L, Mantovani A, Allavena P
    J Immunol, 2016;196(2):902-14.
    Species: Human
    Sample Type: Whole Tissue
    Application: IHC - Paraffin embedded

  2. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease.
    Authors: Brissot E, Bossard C, Malard F, Braudeau C, Chevallier P, Guillaume T, Delaunay J, Josien R, Gregoire M, Gaugler B, Mohty M
    J Leukoc Biol, 2015;97(2):227-35.
    Species: Human
    Sample Type: Whole Tissue
    Application: IHC Paraffin-embedded

  3. Fractalkine-CX3CR1-dependent recruitment and retention of human CD1c+ myeloid dendritic cells by in vitro-activated proximal tubular epithelial cells.
    Authors: Kassianos A, Wang X, Sampangi S, Afrin S, Wilkinson R, Healy H
    Kidney Int, 2015;87(6):1153-63.
    Species: Human
    Sample Type: Whole Tissue
    Application: IHC Frozen

  4. Crosstalk between monocytes and renal mesangial cells via interaction of metalloproteinases and fractalkine in diabetic nephropathy.
    Authors: Wang Y, Wei Q, Liu Q, Li Z, Zhou L, Zou F, Yuan Y, Sun Z
    Mol Med Rep, 2013;8(6):1817-23.
    Species: Human
    Sample Type: Cell Lysates
    Application: WB

  5. Expression and regulation of chemokines in murine and human type 1 diabetes.
    Authors: Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, Eberlein J, Hildemann SK, Homann D
    Diabetes, 2012;61(2):436-46.
    Species: Human
    Sample Type: Whole Cells
    Application: Flow

  6. Fractalkine is a novel human adipochemokine associated with type 2 diabetes.
    Authors: Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, Lu Y, Putt ME, Ahima RS, Reilly MP
    Diabetes, 2011;60(5):1512-8.
    Species: Human
    Sample Type: Whole Cells
    Application: Neut

  7. Thromboxane prostanoid receptor stimulation induces shedding of the transmembrane chemokine CX3CL1 yet enhances CX3CL1-dependent leukocyte adhesion.
    Authors: Tole S, Durkan AM, Huang YW, Liu GY, Leung A, Jones LL, Taylor JA, Robinson LA
    Am. J. Physiol., Cell Physiol., 2010;298(6):C1469-80.
    Species: Human
    Sample Type: Cell Lysates
    Application: WB

  8. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity.
    Authors: Dorgham K, Ghadiri A, Hermand P, Rodero M, Poupel L, Iga M, Hartley O, Gorochov G, Combadiere C, Deterre P
    J. Leukoc. Biol., 2009;86(4):903-11.
    Species: Human
    Sample Type: Virus
    Application: ELISA Development

  9. Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases.
    Authors: Huang YW, Su P, Liu GY, Crow MR, Chaukos D, Yan H, Robinson LA
    J. Biol. Chem., 2009;284(43):29644-53.
    Species: Human
    Sample Type: Whole Cells
    Application: ICC

  10. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism.
    Authors: Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O, Fatatis A
    Cancer Res., 2008;68(6):1715-22.
    Species: Human
    Sample Type: Whole Tissue
    Application: IHC Paraffin-embedded



目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。